0.16%
33.26%
35.32%
67.49%
56.58%
-45.94%
-29.54%
AI Spotlight on APH
Company Description
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas.The company acquires, markets, and distributes consumer healthcare and prescription medicine products.It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products.
The company also offers medical devices, food supplements, and cosmetics.Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names.The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Market Data
| Last Price | 61.3 |
| Change Percentage | 0.16% |
| Open | 61.2 |
| Previous Close | 61.2 |
| Market Cap ( Millions) | 331 |
| Volume | 5530110 |
| Year High | 61.6 |
| Year Low | 24.55 |
| M A 50 | 51.0 |
| M A 200 | 42.2 |
Financial Ratios
| FCF Yield | 5.77% |
| Dividend Yield | 0.00% |
| ROE | -15.24% |
| Debt / Equity | 46.27% |
| Net Debt / EBIDTA | 168.07% |
| Price To Book | 1.49 |
| Price Earnings Ratio | -9.86 |
| Price To FCF | 17.34 |
| Price To sales | 1.81 |
| EV / EBITDA | 8.32 |
News
- Jan -31 - Form 8.3 - Dowlais Group plc
- Jan -28 - Alliance Pharma Leads 3 UK Penny Stocks To Consider
- Jan -23 - Form 8.3 - Direct Line Insurance Group plc
- Jan -21 - Form 8.3 - Direct Line Insurance Group plc
- Jan -20 - Form 8.3 - Direct Line Insurance Group plc
- Jan -15 - Form 8.3 - Hargreaves Lansdown plc
- Jan -14 - Form 8.3 - International Distribution Services plc
- Oct -01 - Alliance Pharma PLC (FRA:DVL) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue ...
- Sep -12 - Alliance Pharma (LON:APH) adds UK£38m to market cap in the past 7 days, though investors from three years ago are still down 58%
- Jun -23 - Recent uptick might appease Alliance Pharma plc (LON:APH) institutional owners after losing 19% over the past year
- Jan -15 - Investors in Alliance Pharma (LON:APH) have unfortunately lost 52% over the last three years
- Oct -19 - Calculating The Intrinsic Value Of Alliance Pharma plc (LON:APH)
- Oct -19 - Calculating The Intrinsic Value Of Alliance Pharma plc (LON:APH)
- May -11 - Investors in Bâloise Holding (VTX:BALN) have unfortunately lost 8.5% over the last year
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Consumer Healthcare
Expected Growth : 3.5 %
What the company do ?
Consumer Healthcare from Alliance Pharma plc is a leading provider of consumer healthcare products, offering a range of brands and products for self-care and wellness.
Why we expect these perspectives ?
Alliance Pharma's Consumer Healthcare segment growth of 3.5% is driven by increasing demand for self-care products, an aging population, and rising healthcare expenditure. Additionally, the company's strategic acquisitions and partnerships have expanded its product portfolio and geographic reach, contributing to growth. Furthermore, the segment's focus on niche and specialty products has helped to mitigate competition and maintain pricing power.
Segment n°2 -> Prescription Medicines
Expected Growth : 4.5 %
What the company do ?
Prescription Medicines from Alliance Pharma plc offers a range of branded prescription medicines for various therapeutic areas, including cardiovascular, dermatology, and oncology.
Why we expect these perspectives ?
Alliance Pharma plc's Prescription Medicines segment growth of 4.5% is driven by increasing demand for specialty pharmaceuticals, strategic product acquisitions, and expansion into emerging markets. Additionally, the company's focus on niche therapeutic areas, such as dermatology and oncology, has contributed to its growth momentum.
Alliance Pharma Plc Products
| Product Range | What is it ? |
|---|---|
| Kelo-cote | A topical silicone gel for the management and prevention of scars |
| MacuShield | A dietary supplement containing meso-zeaxanthin, lutein, and zeaxanthin |
| Xonvea | A prescription-only medication for the treatment of nausea and vomiting in pregnancy |
| Nizoral | A medicated shampoo for the treatment of fungal infections of the scalp |
| Hydromol | A range of emollients for the treatment of dry skin conditions |
Alliance Pharma plc's Porter Forces
Threat Of Substitutes
The threat of substitutes for Alliance Pharma plc is moderate, as there are alternative products available in the market, but they are not significantly cheaper or better than Alliance Pharma's products.
Bargaining Power Of Customers
The bargaining power of customers for Alliance Pharma plc is low, as the company has a diverse customer base and no single customer accounts for a significant portion of its revenue.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Alliance Pharma plc is moderate, as the company relies on a few key suppliers for its raw materials, but it also has some bargaining power due to its size and reputation.
Threat Of New Entrants
The threat of new entrants for Alliance Pharma plc is high, as the pharmaceutical industry is highly competitive and new companies can easily enter the market with innovative products.
Intensity Of Rivalry
The intensity of rivalry for Alliance Pharma plc is high, as the company operates in a highly competitive industry with many established players, and it needs to constantly innovate and differentiate itself to stay ahead.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 31.84% |
| Debt Cost | 6.98% |
| Equity Weight | 68.16% |
| Equity Cost | 6.98% |
| WACC | 6.98% |
| Leverage | 46.71% |
Alliance Pharma plc : Quality Control
Alliance Pharma plc passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| PROB.ST | Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune … |
| BMK.L | Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe … |
| KMDA | Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharmanutra
A-Score
1-Year Total Return ->
🥈
Alliance Pharma
A-Score
1-Year Total Return ->
🥉
Kamada
A-Score
1-Year Total Return ->
4
Benchmark
A-Score
1-Year Total Return ->
5
Probi
A-Score
1-Year Total Return ->
6
